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A B S T R A C T
Recent meta-analysis shows that adherence to a Mediterranean diet (MD) can significantly decrease the risk of over-
all mortality, mortality from cardiovascular diseases, as well as incidence of mortality from cancer, and incidence of Par-
kinson’s and Alzheimer’s disease. All of these diseases could be linked to oxidative stress (OS) as antioxidative effect of
MD is getting more attention nowadays. Although a lot of research has been done in this area and it suggests antioxi-
dative protective role of MD, the presented evidence is still inconclusive. The aim of this paper is to review studies investi-
gating the effect of MD on OS, as well as to identify the areas for further research.
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Introduction
For decades, researchers have been intrigued by the
apparent health benefits of the Mediterranean diet (MD).
A lot of research has been done since the first classical
study in 60’s1–3 and there is numerous evidence of MD’s
beneficial effects. However, there is not a plausible expla-
nation linking MD to all of the collected evidence. Differ-
ent mechanisms of action were proposed for the benefi-
cial effects of MD, some of the most commonly reported
being antiinflamatory, antithrombotic, as well as, anti-
oxidative. Here are some of the clinical findings that sup-
port proposed mechanisms of the MD effects: the change
of carotid intima-media thickness4; down-regulation of
cellular and circulating inflammatory biomarkers rela-
ted to atherogenesis (serum C-reactive protein, inter-
leukin-6 (IL6) and endothelial and monocytary adhesion
molecules and chemokines) in subjects at high cardiovas-
cular risk5; and favorable effects of MD on plasma lipid
profile (reduction of total and plasma LDL cholesterol
levels, plasma triglyceride levels, and apo-B and VLDL
concentrations, and an increase in plasma HDL choles-
terol levels)6.
For a long time the focus of research in MD was on ol-
ive oil as the main source of fat in MD. Therefore, the
benefits on cardiovascular system, known from epidemi-
ological studies were explained through the effect of MD
on lipid profile. Recent meta-analysis shows that adher-
ence to a MD can significantly decrease the risk of overall
mortality, mortality from cardiovascular diseases, as well
as incidence of mortality from cancer, and incidence of
Parkinson’s and Alzheimer’s disease7. There is also large
number of evidence showing that MD may have protec-
tive role against obesity and is associated with reduced
risk of metabolic syndrome8. All of the mentioned evi-
dence could not be linked only to the influence on lipid
markers. However, all of the above mentioned diseases
where MD has been proofed as beneficial could be linked
to the oxidative stress (OS). Therefore, anti-oxidative ef-
fect of MD is getting higher attention nowadays. Al-
though great success has been made in the accumulation
of solid scientific background underlying this topic, there
are still a lot of controversies and full mechanisms of pro-
tection is far from being established. This is partly be-
cause measurement of OS is usually based on indirect
and nonspecific measurement of products of reactive ox-
ygen species (ROS), and there are no standardized or
routine methods of measuring OS. Moreover, measuring
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the anti-oxidative effect of particular diet is an even big-
ger challenge. Numerous parameters aggravate such a
measurement, some of them being: different nutrients of
the diet, the effect of physical activity, lifestyle and many
environmental factors, which all influence the OS. The
aim of this paper is to review studies investigating this
problem, as well as to identify the areas for further re-
search. For that purpose, first we reviewed the diseases
in which OS has been involved, explaining the known
mechanism. Then, we reviewed the individual compo-
nents of MD, known to have anti-oxidative effect. Fur-
thermore, we present the methods used to measure OS
in those studies. At last, we present the evidence of the
effect of MD in different patient groups and discussed
types of studies done, as well as the need for further in-
vestigation. Taking these numerous objectives into con-
sideration, one should keep in mind that limitation of
this review is oversimplification of some of the rather
complex mechanisms. However, the authors wish to pres-
ent the big picture of the subject of interest, accounting
for this important limitation.
Oxidative Stress in Pathology
of Chronic Diseases
OS, an imbalance between the generation of ROS and
antioxidant defense capacity of the body, plays critical
roles in the pathogenesis of various diseases. In the dia-
betic condition, OS impairs glucose uptake in muscle and
fat9,10 and decreases insulin secretion from pancreatic â
cells11. Free radicals are formed disproportionately in dia-
betes by glucose oxidation, nonenzymatic glycation of pro-
teins, and the subsequent oxidative degradation of glyca-
ted proteins12. Abnormally high levels of free radicals and
the simultaneous decline of antioxidant defense mecha-
nisms can lead to damage of cellular organelles and en-
zymes, increased lipid peroxidation, and development of
insulin resistance. These consequences of OS can promote
the development of diabetes mellitus complications13.
Increased OS also underlies the pathophysiology of
hypertension14 and atherosclerosis15 by directly affecting
vascular wall cells. ROS are key mediators of signaling
pathways that underlie vascular inflammation in athero-
genesis, starting from the initiation of fatty streak devel-
opment, through lesion progression, to ultimate plaque
rupture. Many data support the notion that ROS re-
leased from nicotinamide adenine dinucleotide phospha-
te (NADPH) oxidase, myeloperoxidase, xanthine oxidase,
lipoxygenase, nitric oxide synthase and enhanced ROS
production from dysfunctional mitochondrial respiratory
chain, indeed, have a cause-effect role in atherosclerosis
and other vascular diseases16.
Evidence also supports the notion that obesity per se
may induce systemic OS and that increased OS in accu-
mulated fat is, at least in part, the underlying cause of
dysregulation of adipokines and development of meta-
bolic syndrome17. Like in other conditions (i.e. diabetes,
atherosclerosis, hypertension), OS works here in con-
junction with inflammation. Evidence of inflammatory
processes in accumulated fat also appears to be an early
initiator of metabolic syndrome. Likewise, the more ac-
tive angiotensin system in obesity may contribute to
even greater OS that serves as a key signaling event in
vascular remodeling. These factors strengthen obesity’s
association with OS.
Growing data from experimental models and human
brain studies suggest OS may play an important role in
neuronal degeneration in diseases such as Alzheimers’
and Parkinson18. It is still unclear whether OS is the pri-
mary initiating event that is associated with neurode-
generation in Parkinson and Alzheimers’ disease. How-
ever, a growing body of evidence implicates it as being
involved in at least the propagation of cellular injury that
leads to neuropathology in these various conditions. It is
intimately linked with an integrated series of cellular
phenomena, which all seem to contribute to neuronal de-
mise. Interaction between these various components is
not necessarily a cascade but might be a cycle of events,
of which OS is a major component19.
Furthermore, increased formation of ROS can pro-
mote the development of malignancy, and the ‘normal’
rates of ROS generation may account for the increased
risk of cancer development in the aged. Indeed, knockout
of various antioxidant defense enzymes raises oxidative
damage levels and promotes age-related cancer develop-
ment in animals20.
Although, OS has long been linked to the pathology of
the above mentioned diseases, the whole mechanism is
still unclear, leaving an open question whether it is a pri-
mary cause or merely a downstream consequence of
those conditions.
Mediterranean Diet and its Components
There are many variations to the MD, due to social,
political and economic differences between countries in
the Mediterranean region. The concept of the MD is
based on dietary habits more typical of the 1960s, and
rather different for the most part to present Mediterra-
nean lifestyles.
The traditional MD is characterized by a high intake
of vegetables, legumes, fruits and nuts, and cereals (that
in the past were largely unrefined), and a high intake of
olive oil but a low intake of saturated lipids, a moderately
high intake of fish (depending on the proximity of the
sea), a low-to-moderate intake of dairy products (and
then mostly in the form of cheese or yogurt), a low intake
of meat and poultry, and a regular but moderate intake of
ethanol, primarily in the form of wine and generally dur-
ing meals21.
In the past, major emphasis was put on the low satu-
rated fat content of the MD while more recent evidence
has underlined the importance of plant foods rich in anti-
oxidants and omega-3 fatty acids. The Lyon Diet Heart
Study, which was the first clinical trial to show evidence
of health benefits of the MD, proposed that beneficial
components of the MD could be antioxidant-rich foods
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including vegetables, fruits, and their derivatives such as
vinegar, and omega-3-rich fish and canola oils- not olive
oil22. Many studies suggest that a link exists between
fruit and vegetables in the diet or the amounts of plasma
antioxidant vitamins (ascorbic acid, tocopherol and ca-
rotenoids) and a risk of death from cancer or coronary
heart diseases23.
Fruits and vegetables
Public health campaigns recommend increased fruit
and vegetable consumption as an effective mean of car-
diovascular risk reduction. Regular fruit and green vege-
table consumption leads to the accumulation of nitrate /
nitrite / nitric oxide, polyunsaturated fatty acids and
polyphenol compounds. These compounds play an impor-
tant role in protection against myocardial infarction24 and
are associated with OS. Fruit and vegetables are rich
sources of antioxidants, including vitamins, flavonoids,
carotenoids, etc. Water soluble Vitamin C and fat soluble
vitamin E both have well established anti-oxidative prop-
erties. They enhance immune function, protect the body
from free radical damage, and play a role in atherosclerosis.
Besides vitamins, carotenoids (such as lycopene, beta-
-carotene and lutein) are important antioxidants in fruits
and vegetables. Lycopene is a red pigment, found in
many red fruits and vegetables, although the quantity is
higher in cooked tomatoes. Tomato extract or derivative
diet supplements have shown to ameliorate hypertension
and cardiovascular disease, to protect the skin against
the sun (i.e. ultraviolet rays), to decrease the risk of
many chronic diseases including cancer and is antioxi-
dant in many processes25. Sanchez-Moreno and cowor-
kers26 reported that the consumption of gazpacho, a typi-
cal Spanish tomato-based raw vegetable soup, reduced
F2-isoprostanes, a marker of OS, and increased plasma
vitamin C in healthy subjects.
Brassica vegetables, including cabbage, kale, broccoli,
Brussels sprouts, and cauliflower, have been shown to
have protective effects against cancer, probably due to
their relatively high content of glucosinolates27,28. Gluco-
sinolates exhibit their effect by inducing Phase I and
Phase II enzymes, inhibiting the enzyme activation, mo-
difying the steroid hormone metabolism and protecting
against oxidative damages29. Furthermore, indole-3-car-
binol is produced by the breakdown of the glucosinolate
glucobrasicin. Indole-3-carbinol is the subject of on-going
biomedical research into its possible anti-carcinogenic,
anti-oxidant, and anti-atherogenic effects. Some other
bioactive compounds with anti-oxidant activity are: orga-
nosulfur compounds (allicin) found in garlic, onion and
leek; flavonoids (quercitin, kempferol, catechin) in ap-
ples, berries and lettuce; as well as isoflavones (genistein,
daidzein) in legumes30. All of the mentioned substances
are characteristic of MD and showed their antioxidant
properties. However, it is very hard to distinguish their
antioxidant versus other protective mechanisms.
Olive oil
Olive oil (Olea europaea) consumption was associated
with a lower coronary risk and with a reduced breast
cancer risk31,32. Olive oil is rich in several microcom-
ponents that have antioxidant potential33. Oleic acid was
shown to prevent in vitro LDL oxidation34. Phenolic com-
pounds present in olive oil might also contribute to
health benefits derived from the MD.
They reduce the cardiovascular risk factors and down-
-regulate cellular inflammatory pathways related to ath-
erosclerosis, therefore, it seems appropriate to recom-
mend the intake of olive oil to patients in all stages of
atherosclerosis disease35.
The major phenolic compounds identified and quanti-
fied in olive oil belong to three different classes: simple
phenols (hydroxytyrosol, tyrosol); secoiridoids (oleuro-
pein, the aglycone of ligstroside, and their respective
decarboxylated dialdehyde derivatives); and the lignans
[(+)-1-acetoxypinoresinol and pinoresinol]36. All three
classes have potent antioxidant properties. In in vitro37,38
and animal models39,40, olive oil phenolic compounds pro-
tected lipids from oxidation in a dose-dependent manner.
Olive oil’s richness in antioxidants may benefit arterial
blood pressure, reduce LDL-cholesterol, improve diabe-
tes, and reduce the risk of thrombosis25.
Polyunsaturated (PUFA) and
monounsaturated (MUFA) fats
Besides olive oil, the main source of MUFA in MD are
nuts, while source of PUFA is fish, as well as nuts. Regu-
lar consumption of daily serving of mixed nuts (walnuts,
almonds and hazelnuts) has a beneficial effect on some
metabolic syndrome features (high waist circumference,
hipertriglyceridemia, elevated blood pressure, elevated
fasting blood glucose level, low HDL cholesterol level),
which demonstrate that regular nut consumption is as-
sociated with reduced risk of developing coronary heart
disease41.
Beneficial properties of these components of the diet
are related more to anti-inflammatory and vasodilatory
than to antioxidative properties25.
Alcohol
In most of the Mediterranean, wine is consumed in
moderation and usually taken with meals. Studies have
shown that moderate wine consumption increases the an-
tioxidant effects of a MD and decreases oxidative damage42.
Findings from case control study in southern Croatia,
where alcohol consumption is highly prevalent, demon-
strated that moderate alcohol consumption was protective
factor for acute miocardial infarction (OR 0.63)43. Wine,
especially red wine, contains a vast array of phytonu-
trients. Among them, powerful antioxidants polyphenols,
protect against LDL oxidation and other pathological se-
quelae of the OS. The polyphenol resveratrol, present in
grapes, protect vascular walls from oxidation, inflamma-
tion, platelet aggregation, and thrombus formation. Res-
veratrol may act onmultiple levels, such as cellular signal-
ing, enzymatic pathways, apoptosis, and gene expres-
sion25. There are also some studies that show that wine
consumption increases PUFA, omega-3 levels and im-
proves the omega-3: omega-6 fatty acid ratio44.
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Biomarkers of Oxidative Stress in
Epidemiology and Randomized Studies
Many approaches allow evaluation of OS and antioxi-
dant property of particular intervention. Those numer-
ous methodologies are usually categorized into three
main approaches: I) Quantification of radicals; II) Quan-
tification of oxidative damage markers and III) Quantifi-
cation of antioxidant defending system.
In the first group, the well known technique for the
direct detection of radicals is electron spin resonance.
This technique is time consuming, requires a complex
preparation for the samples, and is hardly applicable in
clinical practice due to technical constrains. Therefore,
this method has no practical use in epidemiological or
randomized studies.
For the direct measurement of ROS concentrations
the free oxygen radical test (FORT) technique could be
used, which is simpler and faster45. FORT is based on the
Fenton reaction and measures levels of organic hydro-
peroxides.
However, OS is generally analyzed by measurement of
secondary products (oxidative damage markers). Tech-
niques for quantification of oxidative damage markers
are numerous. They are often called fingerprinting me-
thods, because they measure specific end products result-
ing from the interaction of the ROS with biological
macromolecules, such as DNA, proteins and lipids. The
appearance of these end products serves as proof of the
prior existence of ROS that left their footprints in the
cell.
Among lipid oxidation products commonly measured
markers are malondialdehyde (MDA), thiobarbituric acid
reactive substances (TBARS), and a family of isoprosta-
nes. MDA is one of the terminal aldehyde products of
lipid peroxidation, while TBARS mainly includes MDA.
MDA and other TBARS condense with two equivalents of
thiobarbuturatic acid to give a fluorescent red derivative
that can be assayed spectrophotometrically. In the family
of isoprostanes, F2-isoprostanes are a series of prosta-
glandin F2-like compounds produced through the radi-
cal-catalyzed lipid peroxidation in vivo, independent of
cyclooxygenase. F2-isoprostanes are derived mainly
through the arachidonic acid pathway45. One of the most
abundant F2-isoprostane in humans is 8-epi-PGF2alpha
(8-isoprostane). Urinary or circulating concentrations of
8-isoprostane is used as the biomarker for systemic OS in
the recent years46,47. Other commonly used markers of
lipid oxidation are circulating concentrations of ox-LDL
and autoantibodies against ox-LDL48. Fluorescent oxida-
tion products of lipid peroxidation are the most recent
biomarker for OS49. This fluorescent assay measures the
Schiff base products from interactions of lipid oxidation
products with proteins, amino acids, and DNA oxidation
products.
Evaluation of protein oxidative damage can be accom-
plished using the carbonyl assay50. Carbonyls are pro-
duced from the attack of ROS on amino-acid residues in
proteins. Several methods evaluate these carbonyls, in-
cluding a general estimation of the total carbonyl pool; a
specific determination using gel electrophoresis tech-
niques; and detections of peroxides, loss of SH groups,
loss of fluorescence (eg, tryptophane), chlorination of
proteins, nitration of proteins, and hydroxylation of ami-
no acids.
Furthermore, techniques utilized to detect DNA ad-
ducts and base modification are HPLC or GC-MS analy-
sis of 8-OHdG after enzymatic hydrolysis of DNA and as-
sessment of oxidative base damage by the single-cell gel
electrophoresis, or comet assay50. Other methods exist to
determine single and doublestrand breaks51. Different
oxidized adducts of DNA can be determined. Examples
are DNA aldehyde adducts, such as deoxyguanosine-
-malondialdehyde adducts52, or the end product of the re-
action between DNA and 4-hydroxynonenal, the alde-
hyde formed following exposure to ROS50 to generate
N2-ethenodeoxyguanosine.
Quantification of antioxidant defending system is used
as the third group of methods to indicate OS. Common
antioxidant enzymes include superoxide dismutase (SOD),
glutathione peroxidase (GPx), and catalase (CAT).
Besides antioxidative enzymes, the antioxidant levels
in different biological specimens are measured as well.
Plasma concentrations of vitamin C, alpha-tocopherol,
carotenes, carotenoids, and uric acid are used to reflect
the anti-oxidative defense. Reduced glutathione (GSH),
the smallest intracellular thio (-SH), is a very important
antioxidant molecule. In the reduction-oxidation reac-
tion, GSH is converted to oxidized glutathione, glutathi-
one sulfide (GSSG). The ratio of GSH to GSSG and the
glutathione redox potential for the GSH-GSSG couple
(Eh GSH/GSSG) are measures of OS. A high GSH/GSSG
ratio is essential for protection against OS53. Both glu-
tathione indices may be preferable to either GSH or
GSSG alone as an overall indicator of redox status, be-
cause they quantify the dynamic balance between oxi-
dants and antioxidants54. The higher the GSH/GSSG ra-
tio or the lower the GSSG, the lower the OS.
One of the approaches most commonly used is the
measurement of the total antioxidant activity of a biolog-
ical site. Depletion of one antioxidant molecule causes
changes in the level of overall antioxidant molecules and
may be evaluated using a variety of techniques including
biochemical, immunohistological, spectroscopical, and
electrochemical55. One of the biomarker for antioxidant
capacity is the susceptibility of LDL to metal-induced ox-
idation, measured as the lag time56. The longer the lag
time, the greater is the antioxidant capacity of LDL. An-
other biomarker for antioxidant capacity is total antioxi-
dant capacity (TAC). Several methods have been used to
measure TAC including the oxygen radical absorbance
capacity (ORAC) assay57, the Randox Troloxequivalent
antioxidant capacity (Randox-TEAC) assay58, the ferric
reducing ability (FRAP) assay58, and the detection of re-
active oxygen metabolite (d-ROMS)59.
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Randomized and Epidemiology Trials
Exploring the Effect of Mediterranean
Diet on Oxidative Stress
Research on the association of the MD with OS is lim-
ited with inconsistent results (Table 1). To our knowl-
edge, most of the randomized controlled trials (RCT) in-
volved small sample size (20–51 patients)60–64, with the
exception of PREDIMED study65,66. The PREDIMED
study showed that MD decreased OS after three months
of follow up and enhanced antioxidant defense after
three years of follow up, when comparing low fat diet
with traditional MD (plus virgin olive oil or nuts). De-
creased OS was detected by oxLDL in 372 subjects at
high CV risk and by MDA in subsample of 71 patients,
but no change was observed when measuring GSH-Px in
sample of 372 subjects, while antioxidant defense was
measured by TAC levels in 187 subjects at high CV risk.
Two smaller, intermediate-term RCTs also showed
positive influence of MD on OS, when comparing MD
with a high fat diet in male volunteers after three month
ingestion63, and a low-fat isocaloric diet (2500 kcal for
men, 2000 kcal for women) in kidney grafting patients
over six month intervention65, respectively.
On the contrary, three RCTs failed to show the favor-
able effect of a MD on OS in comparison with a Swedish
diet60,62 and very-low-carbohydrate diet61. These were
4-week intervention conducted in healthy subjects60; a
3-week intervention performed in patients with rheuma-
toid arthritis62; and a two months intervention in over-
weight and obese women61. In these trials, OS has been
measured with various markers, such as plasma antioxi-
dants (vitamin C63, gamma-tocopherol62, beta-carotene62,
lycopene62, and uric acid62), plasma lipid peroxidation
products (TBARS64 and MDA62), antioxidant enzymes
(erythrocyte SOD65, oxidative DNA damage63, and uri-
nary F2-isoprostane60).
Besides these RCT, the epidemiology study ATTICA67,
which involved 3042 healthy subjects from province of
Greece, found positive correlation of MD with total anti-
oxidant capacity and those who adhere more to MD (cal-
culated by med diet scores) had higher TAC levels. More-
over, Dai68 showed in well controlled study of twins that
one unit increment in the Mediterranean diet score was
associated with 7% higher GSH/GSSG ratio, meaning
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TABLE 1
RANDOMIZED AND EPIDEMIOLOGICAL TRIALS EXPLORING THE EFFECT OF MD ON OS
Author/Year
of Publica-
tion
Subjects Design of the
study
Diet/ Diet
groups
Oxidative stress
parameter mea-
sured
Results
Razquin et
al.66, 2009
187 subjects at
high CV risk
RCT,
FU: 3 years
I. control = low
fat diet (59 sub-
jects);
II. TMD+VOO
(65 subjects);
III. TMD+ Nuts
(65 subjects)
TAC (commer-
cially available
colorimetric assay
kit)
TAC in both TMD+VOO and
TMD+nuts groups. Both chan-
ges were statistically significant
vs. control (p<0.001)
Fito et al.65,
2007
372 subjects at
high CV risk (71
subject randomly
selected subsample
for MDA measure-
ment)
RCT,
FU: 3 months
I. control= low fat
diet (121 subjects);
II. TMD+VOO
(123 subjects);
II. TMD+ nuts
(128 subjects)
oxLDL (enzyme-
-linked immuno-
sorbent assay us-
ing the mAbE6
antibody),
oxLDL ¯ in TMD+VOO and
TMD+nuts groups. Only chan-
ge in TMD+VOO vs. low fat
group was significant (p=0.02)
GSH-Px by spec-
trophotometry
No changes were observed
MDA in mononu-
clear cells by
HPLC
Changes paralleled those of
oxLDL
Dai et al.68,
2008
138 monogygotic
and dizygotic twin
pairs and 21 un-
paired twins
Cross-sectional
survey
Diet assessed by
FFQ; adherence to
MD assessed on
the basis of a MD
score
GSH/GSSG ratio
(higher the ratio
= lower the OS)
One-unit in the diet score as-
sociated with 7% higher
GSH/GSSG ratio (p=0.03).
Pistavos et
al.67, 2005
(ATTICA
study)
3042 healthy
subjects from
province of Attica
(Greece)
Cross-sectional
survey
Diet assessed by
FFQ; adherence
to MD assessed
on the basis of a
MD score
TAC (immune-di-
agnostic assay)
TAC positively correlated with
diet score; highest tertile of the
diet score had 11% higher TAC
levels than lowest tertile
(p<0.01)
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lower OS. This association was not confounded by con-
ventional risk factors, familial influences or genetic factors.
Discussion and Conclusion
Recent evidence shows the positive impact of MD on
OS, but data is still scarce. Results from smaller size tri-
als are inconsistent, while bigger size trails are missing.
The only available big, longer term RCT contribute to
the understanding of the influence of MD on antioxi-
dative capacity, while shorter term RCT showed the in-
fluence of MD on oxLDL, both in high CV risk patients.
However, data for other patient groups is still inconclu-
sive.
In this review, we explored the problems one could ex-
perience when designing the study that aims to explore
the effect of MD on OS. First of all, in clinical practice
and epidemiological or RCTs, an ideal method of measur-
ing OS is not currently available. In order to get the most
out of the presently available techniques it’s important
that they are used intelligently69.
Furthermore, in all of the diseases mentioned in this
review, more pathways are involved in their pathology
besides OS and usually there is interaction between
some of them, such as OS and inflammation in athero-
sclerosis, diabetes or obesity. Therefore, it makes it
difficult to measure MD contribution to only the antioxi-
dant mechanism. Our recommendation for the future re-
search would be to involve more parameters in order to
account for their interactions. Also, controversy exists
whether the increased OS is merely associative rather
than causal in those diseases and makes it difficult to dif-
ferentiate between the preventive and therapeutic effect
of MD on OS. Therefore, both epidemiological and ran-
domized controlled trials are needed, and should be tai-
lored to explore the influence of MD in different stages of
the diseases.
Other complicating factors are different food compo-
nents, involved in the diet, that could be responsible for
antioxidant properties, and it is very hard to tailor the
best diet, both during the research and in the clinical
practice. Therefore, scientists should agree on the stan-
dard MD to be used in the research. Also, the methods for
measuring compliance to diet are matter of scientist’s
discussion, but that is not in the scope of this review.
Moreover, other influences, such as physical activities
contribute to OS and their contribution was rarely ac-
counted in such trials.
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Hagfors et
al.62, 2003
51 rheumatoid
arthritis patients
(10 M, 41 F)
RCT,
FU: 3 months
I. MD
II. control (partici-
pants normal diet)
Plasma levels of
retinol, antioxi-
dants (á- i ã-toco-
pherol, â-carotene,
lycopãene, vitamin
C and uric acid)
and urinary MDA
No changes in urine MDA or
plasma levels of antioxidants
Leigton et
al.63, 1999
42 M RCT,
FU: 3 months
I. MD
II. Western diet
(high fat diet)
Plasma vitamin C
and E, TAC, oxida-
tive DNA damage
in blood leukocyte
DNA (8-OHdG
levels)
The MD TAC (28%). The high
fat diet ¯ vitamin C levels, and
oxidative DNA damage, sig-
nificantly. Both diets showed
lower OS and higher antioxida-
tive status when wine was
added
Ambring et
al.60, 2004
22 healthy sub-
jects (12 M, 10 F)
R-crossover-CT,
FU: 4 weeks +
4 weeks wash out
+ 4 weeks
I. Swedish diet
II. MD rich in ù-3
fatty acids and
sterol esters
8-iso-PGF2á in
urine
No effect on 8-iso-PGF2á
Buscemi et
al.61, 2009
20 overweight/
obese women
RCT,
FU: 2 months
I. very -low-car-
bohydrate diet
II. MD
8-iso-PGF2á in
serum
No effect on 8-iso-PGF2á after 2
months. 8-iso-PGF2á signifi-
cantly only after 5 days in very-
-low-carbohydrate group
Stachowska
et al.65, 2005
37 kidney graft
recipients
RCT,
FU: 6 months
I. MD (21 pt)
II. Low fat diet
(16 pt)
á-tocopherol in
plasma, TBARS in
plasma and eryth-
rocytes, and the
activities of SOD,
catalase and GSH-
Px in erythrocytes
In MD group SOD (p<0.001
after 6 months), catalase ¯
(p<0.001 after 6 months) and
GSH-Px ¯ (P<0.05 after 2
months), TBARS in plasma ¯
(p<0.05 after 6 months),
á-tocopherol unchanged
RCT – randomized controlled trial, FU – follow up, CV- cardiovascular, TMD – traditional mediterranean diet, VOO – virgin olive oil,
TAC – total antioxidant capacity, GSH-Px – glutathion peroxidase, MDA – malondialdehyde, oxLDL – oxidized low density lipoprotein,
FFQ – food frequency questionnaire, 8-OhdG – 8-hydroxydeoxyguanosine, OS – oxidative stress, 8-iso-PGF2á – prostaglandin F2á,
TBARS – thiobarbituric acid-reactive species, SOD – superoxide dismutas
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Most of the larger studies were done in Mediterra-
nean countries (Greece and Spain)65–67 and one could ar-
gue that the applicability of the results to non-Mediterra-
nean countries could be questioned. Therefore, there is
need for multinational randomized trials in the future.
Altogether, there is need for larger, long-term ran-
domized trials in different patient groups and future
work should be thoughtfully designed to overcome some
of the problems mentioned.
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ANTIOKSIDATIVNO PROTEKTIVNO DJELOVANJE MEDITERANSKE DIJETE
S A @ E T A K
Nedavna meta analiza je pokazala da pridr`avanje mediteranskoj dijeti zna~ajno smanjuje rizik od ukupne smrt-
nosti, smrtnosti od kardiovaskularnih bolesti i karcinoma, te pojavnost Parkinsonove i Alzheimerove bolesti. Kako se
sve spomenute bolesti dovode u vezu sa oksidacijskim stresom, mediteranska prehrana sa svojim antioksidativnim
u~inkom, danas dobiva sve ve}u pozornost. Danas postoji mnogo istra`ivanja u tom podru~ju, koja ve}inom upu}uju na
antioksidativno, protektivno djelovanje mediteranske preherane. Usprkos tome, me|u postoje}im dokazima postoji do-
sta proturije~nosti. Cilj ovog rada bio je prou~iti studije koje su se bavile utjecajem mediteranske prehrane na oksida-
cijski stress, te ustanoviti podru~je od zna~aja za dalja istra`ivanja.
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